BMY logo

Bristol-Myers Squibb (BMY) Accounts receivable

Annual accounts receivable:

$9.01B+$130.00M(+1.46%)
December 31, 2024

Summary

  • As of today (May 30, 2025), BMY annual accounts receivable is $9.01 billion, with the most recent change of +$130.00 million (+1.46%) on December 31, 2024.
  • During the last 3 years, BMY annual accounts receivable has risen by +$1.03 billion (+12.95%).
  • BMY annual accounts receivable is now at all-time high.

Performance

BMY Accounts receivable Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherBMYbalance sheet metrics

Quarterly accounts receivable:

$9.06B+$51.00M(+0.57%)
March 31, 2025

Summary

  • As of today (May 30, 2025), BMY quarterly accounts receivable is $9.06 billion, with the most recent change of +$51.00 million (+0.57%) on March 31, 2025.
  • Over the past year, BMY quarterly accounts receivable has increased by +$237.00 million (+2.69%).
  • BMY quarterly accounts receivable is now -7.01% below its all-time high of $9.75 billion, reached on June 30, 2024.

Performance

BMY Quarterly accounts receivable Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherBMYbalance sheet metrics

Accounts receivable Formula

Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales

BMY Accounts receivable Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year+1.5%+2.7%
3 y3 years+12.9%+26.6%
5 y5 years+39.2%+25.9%

BMY Accounts receivable Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-yearat high+12.9%-7.0%+26.6%
5 y5-yearat high+39.2%-7.0%+35.3%
alltimeall timeat high+433.3%-7.0%+458.4%

BMY Accounts receivable History

DateAnnualQuarterly
Mar 2025
-
$9.06B(+0.6%)
Dec 2024
$9.01B(+1.5%)
$9.01B(-3.3%)
Sep 2024
-
$9.32B(-4.4%)
Jun 2024
-
$9.75B(+10.4%)
Mar 2024
-
$8.83B(-0.6%)
Dec 2023
$8.88B(+9.0%)
$8.88B(+5.7%)
Sep 2023
-
$8.41B(+3.5%)
Jun 2023
-
$8.13B(+3.5%)
Mar 2023
-
$7.85B(-3.6%)
Dec 2022
$8.15B(+2.2%)
$8.15B(+1.6%)
Sep 2022
-
$8.02B(+5.7%)
Jun 2022
-
$7.59B(+6.0%)
Mar 2022
-
$7.16B(-10.3%)
Dec 2021
$7.98B(+10.5%)
$7.98B(+1.3%)
Sep 2021
-
$7.88B(+2.1%)
Jun 2021
-
$7.71B(+7.3%)
Mar 2021
-
$7.19B(-0.4%)
Dec 2020
$7.22B(+11.5%)
$7.22B(+6.5%)
Sep 2020
-
$6.78B(+1.2%)
Jun 2020
-
$6.70B(-7.0%)
Mar 2020
-
$7.20B(+11.2%)
Dec 2019
$6.48B(+39.7%)
$6.48B(+51.0%)
Sep 2019
-
$4.29B(-4.8%)
Jun 2019
-
$4.50B(-2.0%)
Mar 2019
-
$4.59B(-0.9%)
Dec 2018
$4.64B(+6.6%)
$4.64B(+0.3%)
Sep 2018
-
$4.62B(+6.9%)
Jun 2018
-
$4.32B(-1.2%)
Mar 2018
-
$4.37B(+0.6%)
Dec 2017
$4.35B(+15.2%)
$4.35B(+0.3%)
Sep 2017
-
$4.33B(+2.7%)
Jun 2017
-
$4.22B(+3.3%)
Mar 2017
-
$4.08B(+8.2%)
Dec 2016
$3.77B(+28.0%)
$3.77B(-1.0%)
Sep 2016
-
$3.81B(+3.5%)
Jun 2016
-
$3.69B(+9.6%)
Mar 2016
-
$3.36B(+14.1%)
Dec 2015
$2.95B(+40.4%)
$2.95B(+8.6%)
Sep 2015
-
$2.71B(+6.7%)
Jun 2015
-
$2.54B(+13.0%)
Mar 2015
-
$2.25B(+7.1%)
Dec 2014
$2.10B(+24.3%)
$2.10B(+15.2%)
Sep 2014
-
$1.82B(+1.3%)
Jun 2014
-
$1.80B(+3.3%)
Mar 2014
-
$1.74B(+3.1%)
Dec 2013
$1.69B
$1.69B(-8.1%)
Sep 2013
-
$1.84B(-0.6%)
DateAnnualQuarterly
Jun 2013
-
$1.85B(+2.9%)
Mar 2013
-
$1.80B(+5.3%)
Dec 2012
$1.71B(-24.1%)
$1.71B(-1.5%)
Sep 2012
-
$1.73B(+6.8%)
Jun 2012
-
$1.62B(-55.1%)
Mar 2012
-
$3.61B(+60.6%)
Dec 2011
$2.25B(-46.9%)
$2.25B(+3.2%)
Sep 2011
-
$2.18B(+3.1%)
Jun 2011
-
$2.12B(+3.4%)
Mar 2011
-
$2.05B(+13.4%)
Jun 2010
-
$1.80B(-57.3%)
Sep 2008
-
$4.22B(-5.5%)
Jun 2008
-
$4.47B(-1.6%)
Mar 2008
-
$4.54B(+7.1%)
Dec 2007
$4.24B(+30.6%)
$4.24B(+14.5%)
Sep 2007
-
$3.70B(+2.0%)
Jun 2007
-
$3.63B(+7.4%)
Mar 2007
-
$3.38B(+4.1%)
Dec 2006
$3.25B(-3.9%)
$3.25B(+10.3%)
Sep 2006
-
$2.94B(-11.5%)
Jun 2006
-
$3.33B(+2.8%)
Mar 2006
-
$3.24B(-4.2%)
Dec 2005
$3.38B(-22.8%)
$3.38B(+2.2%)
Sep 2005
-
$3.31B(-0.3%)
Jun 2005
-
$3.31B(-9.1%)
Mar 2005
-
$3.65B(-16.6%)
Dec 2004
$4.37B(+19.5%)
$4.37B(+14.8%)
Sep 2004
-
$3.81B(+8.6%)
Jun 2004
-
$3.51B(+12.9%)
Mar 2004
-
$3.11B(-15.1%)
Dec 2003
$3.66B(+23.3%)
$3.66B(+2.0%)
Sep 2003
-
$3.59B(+11.7%)
Jun 2003
-
$3.21B(+0.8%)
Mar 2003
-
$3.19B(+7.4%)
Dec 2002
$2.97B(-25.7%)
$2.97B(-17.9%)
Sep 2002
-
$3.62B(+4.2%)
Jun 2002
-
$3.47B(-3.6%)
Mar 2002
-
$3.60B(-9.8%)
Dec 2001
$3.99B(+9.0%)
$3.99B(+6.8%)
Sep 2001
-
$3.74B(+5.3%)
Jun 2001
-
$3.55B(-10.0%)
Mar 2001
-
$3.95B(+7.8%)
Dec 2000
$3.66B(+11.9%)
$3.66B(-3.2%)
Sep 2000
-
$3.78B(+15.6%)
Dec 1999
$3.27B(+2.6%)
$3.27B(+2.6%)
Dec 1998
$3.19B(+7.3%)
$3.19B(+1.9%)
Sep 1998
-
$3.13B(+5.2%)
Dec 1997
$2.97B
$2.97B

FAQ

  • What is Bristol-Myers Squibb annual accounts receivable?
  • What is the all time high annual accounts receivable for Bristol-Myers Squibb?
  • What is Bristol-Myers Squibb annual accounts receivable year-on-year change?
  • What is Bristol-Myers Squibb quarterly accounts receivable?
  • What is the all time high quarterly accounts receivable for Bristol-Myers Squibb?
  • What is Bristol-Myers Squibb quarterly accounts receivable year-on-year change?

What is Bristol-Myers Squibb annual accounts receivable?

The current annual accounts receivable of BMY is $9.01B

What is the all time high annual accounts receivable for Bristol-Myers Squibb?

Bristol-Myers Squibb all-time high annual accounts receivable is $9.01B

What is Bristol-Myers Squibb annual accounts receivable year-on-year change?

Over the past year, BMY annual accounts receivable has changed by +$130.00M (+1.46%)

What is Bristol-Myers Squibb quarterly accounts receivable?

The current quarterly accounts receivable of BMY is $9.06B

What is the all time high quarterly accounts receivable for Bristol-Myers Squibb?

Bristol-Myers Squibb all-time high quarterly accounts receivable is $9.75B

What is Bristol-Myers Squibb quarterly accounts receivable year-on-year change?

Over the past year, BMY quarterly accounts receivable has changed by +$237.00M (+2.69%)
On this page